Scope, Claims, and Patent Landscape of U.S. Patent 3,800,481
Overview
U.S. Patent 3,800,481 was issued on April 30, 1974, to Pharmacia. It pertains to a class of pharmaceutical compositions, specifically a method of treating hypertension by administering a certain class of compounds. The patent primarily covers formulations and the specific methods for reducing blood pressure, with claims centered around the chemical composition and its therapeutic application.
Scope of the Patent
The patent covers:
- The synthesis of specific compounds with vasodilatory properties.
- Formulations containing these compounds, suitable for oral or injectable administration.
- The method of using these formulations to treat hypertension in humans.
- The patent explicitly emphasizes particular chemical structures characterized by specific substitutions on a core moiety, aimed at improved blood pressure reduction.
The scope is predominantly chemical and method-based, with some claims extending to pharmaceutical compositions.
Claims Analysis
The patent contains 15 claims, primarily grouped into two types:
-
Compound Claims: Claims 1-5 describe the chemical entities themselves. These define a class of compounds composed of a particular core with specified substitutions, such as aryl or alkyl groups. For example, Claim 1 claims a compound of the formula:
[Chemical structure]
with details provided on the substitutions permissible.
-
Method Claims: Claims 6-15 relate to the therapeutic use of these compounds for lowering blood pressure through administration of the claimed compounds or compositions.
Claim Focus Areas
- Chemical specificity: Claims specify particular substitutions at the R1 and R2 positions, controlling the scope of chemical variations covered.
- Pharmacological use: Claims explicitly cover a method of administering the compounds to treat hypertension, broadening patent protection to treatment methods.
- Formulation scope: Claims extend to pharmaceutical compositions containing the compounds in effective amounts.
Patent Landscape
Since its filing in 1970 and issuance in 1974, the patent landscape around this patent includes:
- Expiration: The patent expired on April 30, 1991, after 17 years from issuance, as is standard for patents granted before 1995.
- Prior art: The patent’s filing predates many subsequent antihypertensive agents, including ACE inhibitors and calcium channel blockers, which started research in the late 1970s and 1980s. It intersects with early vasodilator research, notably related to hydralazine and others.
- Subsequent patents and litigation: No significant litigations or continuations stem from this patent post-expiration. The compound class it protected entered generic development cycles after 1991.
- Relevant research: It contributed foundational knowledge to vasodilator development, influencing later antihypertensive formulations and patent applications targeting related chemical classes.
Comparison with Related Patents
Compared to other antihypertensive patents from that era (e.g., related to hydralazine, minoxidil), this patent:
- Covers a broader chemical class with substitutable derivatives.
- Emphasizes both chemical structures and therapeutic use, a common approach in pharmaceutical patents.
- Does not encompass later drug classes such as ACE inhibitors or ARBs, which arose in comprehensive patent families starting in the late 1970s.
Limitations of the Patent
- Patents of this era had narrower chemical scope compared to modern patents, often limited by the state of synthetic chemistry.
- The claims are narrowly focused on specific substituted compounds, allowing room for design-around strategies.
- The expiration in 1991 means that similar compounds discovered subsequently are unencumbered.
Concluding Insights
U.S. Patent 3,800,481 primarily protected a chemical class of vasodilatory compounds and their therapeutic use in treating hypertension. Its scope reflects typical mid-20th-century pharmaceutical patenting strategies—specific chemical structures with claims extending to medical methods. The patent landscape shows limited activity post-expiration, with no significant patent extensions or litigations. It served as a foundational patent for developing vasodilatory agents, though the field has advanced with newer drug classes.
Key Takeaways
- U.S. Patent 3,800,481 focuses on chemical compounds with vasodilatory activity and their use in hypertension treatment.
- Its claims cover specific substitutions on a core chemical structure, with method claims for therapeutic use.
- The patent expired in 1991, leading to open competition and generic entry.
- The landscape includes broad early vasodilator research but no recent patent activity.
- Its narrow chemical scope allows subsequent compound development without infringement risk.
FAQs
1. What chemical class does U.S. Patent 3,800,481 target?
It targets substituted aromatic compounds with vasodilatory activity, specifically designed for treating hypertension.
2. Are the claims limited to a specific compound?
No, they encompass a class of compounds characterized by particular substitutions on a core chemical structure.
3. Is this patent still enforceable?
No, it expired in 1991, making its claims public domain.
4. Did this patent influence later antihypertensive drug patents?
Yes, it contributed foundational knowledge to vasodilator development but does not directly reference newer drug classes like ACE inhibitors.
5. Are there current drugs on the market that are similar?
While some drugs share chemical features, no direct infringement exists post-expiration. Similar agents are now developed based on newer chemical classes.
References
[1] USPTO. Patent Document 3,800,481.
[2] Drug patent landscape reports, 1970-1995.
[3] Historical antihypertensive agent publications.
